What we mean
A company can usually see what it has to do next. Finish a trial. Deliver a first commercial contract. Integrate an acquisition. Repair a balance sheet before the market will look at it again.
The difficulty is that the market will not price the step until it has been taken. Equity issued before the step is punitively dilutive. Bank debt is not available at this size. The window is measured in months, and the company is on the landing.
That is where we invest. What usually sits on the other side of the step is a larger specialist investor — one that could not price the company until the step had been taken. The four situations below are drawn from transactions the team has completed. Three worked. The fourth is what happens when the step does not arrive, which is the part of the record that matters most to anyone deciding whether to bring us a company.
Companies are not named and figures are rounded.
Case one
Life sciences · Scandinavia · Listed
The situation
A listed biotech carrying a market capitalisation of about $15 million. The science was credible and the clinical programme was already part-completed. What remained was the most expensive and highest-risk portion of the study — the part that would either validate the asset or end it.
The palier
Nobody prices a binary before it resolves. Issuing equity at a $15 million valuation would have cost the existing holders most of the company to fund a step that, if it worked, would make the company worth many times that. Lenders do not take clinical risk at all. The company could see the readout and could not reach it.
What we did
Funded the remaining phase of the study. Not the safe part around it — the part the risk actually sat in, which is where the gap was and therefore where the capital was needed.
Where it stands
The data read out well, and the company raised its next round from a large fund specialising in the sector — the investor that could not price it beforehand. Its market capitalisation moved from roughly $15 million to roughly $300 million.
Case two
Clean energy · France · Euronext Growth
The situation
A hydrogen mobility company listed in Paris. We came in early, with cash to carry the company to a much larger raise planned for after the Salon de l’Automobile. The show went well. A few months later the market turned, and the round the whole plan rested on was no longer there.
The palier
The gap had been a short one: from the motor show to the raise. It became a different gap altogether — from a court-supervised procedure back to a company that could trade. Nobody funds that stretch. It is the point at which a listed company holding real technology is usually broken up, sold abroad, or simply stops.
What we did
We took the view that the business was worth saving and that a court restructuring was the honest route to it, rather than financing a decline. We supported the application, then financed the entire period of the procedure — the months in which no other money exists.
We worked with management to restructure the company and its debt, put in further new money, and financed the plan that took it out of receivership. The next phase, an acquisition to give the company an operating base again, is under way.
Where it stands
Creditors recovered part of what they were owed, where the ordinary path would have returned very little. The business continued, smaller but intact, with jobs that would otherwise have gone. And the technology stayed in France, rather than being sold abroad or written off.
Case three
Mining · London listed · African asset
The situation
An African vanadium project, AIM-listed, that was very nearly a mine. The orebody was proven and the plant was substantially in place. What was missing was the last stretch of capital — the part that turns construction into production.
The palier
The market prices producing mines, and it prices exploration. It does not price the ground between them, where the capital has already gone in and the revenue has not started. Equity raised at that point is priced as though the company still produces nothing, because it does.
What we did
Put in $8 million to finish the mine and take it into production.
Where it stands
Production started, and the company raised from a large fund specialising in resources — the capital that was never available while the mine was unfinished. Over the life of the investment its market capitalisation moved from around $50 million to around $500 million.
Case four
Battery metals · London · AIM
The situation
A battery-metals recycling and exploration group, funded through a convertible facility while it built out processing capacity.
The palier
It did not arrive. Production timelines slipped, the equity market closed behind the company, and the facility could not be serviced on its original terms.
What we did
Enforcement was available and would have ended the company. We renegotiated instead, into a settlement of approximately £1.7 million: part in cash, part in shares, and the balance as a term loan the business could carry.
Recovery was spread over time rather than taken at once. That is the only version of this in which the company is still there afterwards, and it is the version we would want on the other side of the table.
Where it stands
Settled in 2026. The company is trading and turning: the board has been cleaned up and a first acquisition completed. The settlement left it able to do both, which is the whole argument for restructuring rather than enforcing.
These summaries describe transactions completed by the team and by ventures the partners have been part of. Companies are not identified, figures are rounded and terms are summarised. Past transactions are not a guide to future results, and nothing here is an offer of securities or investment advice.
Nothing on this site is an offer of securities or investment advice.
© 2026 Palier Capital